EpiBone to Start Clinical Trials for Knee Cartilage Grown in Lab

JERSEY CITY, N.J.July 24, 2023 /PRNewswire/ — EpiBone has received Investigational New Drug (IND) clearance from the FDA to begin testing its lab-grown knee cartilage in humans. The treatment, known as an engineered allogenic osteochondral graft, has shown promise in pre-clinical studies and could benefit people with damaged knee cartilage caused by sports injuries, trauma or post-traumatic arthritis.

Clinical trials will evaluate the safety and efficacy of EpiBone’s graft compared to current treatment, with patient recruitment set to begin as soon as early 2024.

“Sports injuries are becoming more common, particularly in young people who need their knees to function for many years to come. Yet they often have limited treatment options that don’t fully alleviate their symptoms,” said Nina Tandon, Co-Founder and CEO of EpiBone. “With this lab-grown living cartilage, we are able to offer patients a new avenue to harness the power of living cells to help cartilage heal when it normally is notoriously slow to recover from injury, if it recovers at all.”

The graft could offer an alternative for osteochondral allografts, which are donor plugs of cartilage taken from cadavers, and while efficacious, are in short supply – only about 2,500 each year – not enough for the growing number of patients whose knees are damaged.

EpiBone seeks to solve this supply constraint by cultivating the grafts in the lab, eliminating risks of disease transmission and donor matching issues. The process involves placing bone marrow stem cells on a scaffold in the lab, maturing them into cartilage cells through a proprietary technique, and then utilizing the living cartilage to treat various-size defects. Once implanted, the new graft has potential to mature and integrate with surrounding tissues.

This innovative treatment was first tested in an equine study conducted by Cornell University’s College of Veterinary Medicine, which demonstrated that EpiBone’s graft integrated better with surrounding cartilage than the current gold standard of using donor tissue. Those findings were shared in April at the Focus Meeting of the International Cartilage Regeneration & Joint Preservation Society.

This is EpiBone’s second product to advance into clinical trials. The company is approaching the end of its first clinical trial, using a patient’s own stem cells to grow living anatomically precise bone grafts.

About EpiBone

EpiBone, Inc. is a privately-held regenerative medicine company focused on skeletal reconstruction. Sitting at the intersection of biology and engineering, the company harnesses the power of cells to create living solutions that become a seamless part of a patient’s body. EpiBone is currently developing a pipeline of bone, cartilage, and other skeletal tissue products. For more information, visit epibone.com.


This communication contains forward-looking statements, which can generally be identified by words such as “plans,” “change,” “will,” “following”, “strengthening,” “developing,” the negative of these words and similar words and expressions, which are based on EpiBone’s current expectations, assumptions, estimates and projections about its business, technology, product development and industry. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and include, without limitation, EpiBone’s ability to (1) adequately protect or enforce its intellectual property rights, (2) develop and commercialize new products and technologies on a timely basis (or at all), (3) risks associated with acquisitions and strategic investments and (4) attract and retain qualified personnel. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. Additionally, this communication does not constitute an offer to sell or a solicitation of an offer to buy securities.

SOURCE EpiBone, Inc.

About Peter Coffaro 506 Articles
Peter Coffaro is a growth-driven and strategic executive with over 25 years of progressive management success in the medical device industry. With a proven track record and recognized expertise, Peter has established himself as one of the top influencers in medical sales, as acknowledged by prestigious publications such as the World Journal of Orthopedics, Exponential Healthtech, and MedReps.com. Throughout his career, Peter has accumulated 10 years of combined sales management experience, excelling in various roles including Director, General Manager, Distributor, and Vice President. He has worked for industry-leading orthopedic companies such as Zimmer, DePuy, and Stryker, solidifying his deep knowledge and network within the field. Peter’s passion for innovation and emerging technologies led him to found OrthoFeed, an award-winning blog covering digital orthopedic news and emerging medical technologies. Through this platform, he stays at the forefront of the industry and contributes to the dissemination of valuable insights. Peter is a three-time Hall of Fame award winner at Johnson and Johnson, demonstrating his exceptional contributions and impact on the organization. His expertise extends to areas such as organizational development, business development, sales management, digital marketing, and professional education. Peter earned a B.S. degree in Biology and Chemistry from Northern Illinois University, further complementing his comprehensive understanding of the medical field. With his wealth of experience, strategic mindset, and dedication to advancing healthcare, Peter Coffaro is a valuable asset and leader in the medical device industry.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.